Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166081 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
A Phase 1 study of Non-diabetic Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07166081: Recruiting Phase 1 study of Non-diabetic Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co..
NCT07166081 is a Phase 1 study of Non-diabetic Overweight or Obese that is actively recruiting participants, run by BrightGene Bio-Medical Technology Co.. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07166081, a Phase 1 study of Non-diabetic Overweight or Obese, is actively recruiting participants, sponsored by BrightGene Bio-Medical Technology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BGM0504
Study Locations (1)
Maryland
- Pharmaron CPC, Inc - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2026-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07166081
The ClinicalTrials.gov registry entry for NCT07166081 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). The listed sponsor is BrightGene Bio-Medical Technology Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-diabetic Overweight or Obese appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07166081 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07166081 about?
NCT07166081 is a clinical study titled "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects". This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult sub...
What is the current status of trial NCT07166081?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-08-11. Estimated completion is 2026-05-13.
What conditions does trial NCT07166081 study?
This clinical trial studies the following conditions: Non-diabetic Overweight or Obese.
What interventions are being tested in trial NCT07166081?
The interventions under investigation include: Placebo (DRUG), BGM0504 (DRUG).
Who is sponsoring clinical trial NCT07166081?
This trial is sponsored by BrightGene Bio-Medical Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07166081 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.